ZA200804307B - Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor - Google Patents
Ligands that have binding specificity for EGFR and/or VEGF and methods of use thereforInfo
- Publication number
- ZA200804307B ZA200804307B ZA200804307A ZA200804307A ZA200804307B ZA 200804307 B ZA200804307 B ZA 200804307B ZA 200804307 A ZA200804307 A ZA 200804307A ZA 200804307 A ZA200804307 A ZA 200804307A ZA 200804307 B ZA200804307 B ZA 200804307B
- Authority
- ZA
- South Africa
- Prior art keywords
- egfr
- vegf
- ligands
- methods
- binding specificity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74299205P | 2005-12-06 | 2005-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200804307B true ZA200804307B (en) | 2009-09-30 |
Family
ID=37820651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200804307A ZA200804307B (en) | 2005-12-06 | 2008-05-19 | Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100021473A1 (fr) |
EP (1) | EP1963370A1 (fr) |
JP (1) | JP2009518025A (fr) |
KR (1) | KR20080090414A (fr) |
CN (2) | CN101426815A (fr) |
AU (1) | AU2006323415A1 (fr) |
BR (1) | BRPI0619460A2 (fr) |
CA (1) | CA2632424A1 (fr) |
CR (1) | CR10100A (fr) |
EA (1) | EA200801171A1 (fr) |
MA (1) | MA30020B1 (fr) |
NO (1) | NO20082381L (fr) |
TW (1) | TW200738750A (fr) |
WO (1) | WO2007066109A1 (fr) |
ZA (1) | ZA200804307B (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006519763A (ja) | 2002-11-08 | 2006-08-31 | アブリンクス エン.ヴェー. | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
JP5817034B2 (ja) | 2007-12-26 | 2015-11-18 | バイオテスト・アクチエンゲゼルシヤフト | Cd138を標的とする免疫複合体及びその使用 |
JP2011507933A (ja) * | 2007-12-26 | 2011-03-10 | バイオテスト・アクチエンゲゼルシヤフト | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
AR069978A1 (es) * | 2007-12-26 | 2010-03-03 | Dana Farber Cancer Inst Inc | Metodos y agentes para mejorar el reconocimiento de celulas de tumor que expresan cd 138 |
EP2238168B8 (fr) * | 2007-12-26 | 2014-07-23 | Biotest AG | Agents ciblant cd138 et leurs applications |
CA2711256C (fr) | 2008-01-03 | 2019-01-15 | The Scripps Research Institute | Ciblage d'anticorps par domaine de reconnaissance modulaire |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US9198952B2 (en) | 2008-09-22 | 2015-12-01 | The Brigham And Women's Hospital, Inc. | Compositions of and methods of using ligand dimers |
MX2011004244A (es) * | 2008-10-21 | 2011-05-25 | Domantis Ltd | Ligandos que tienen especificidad de enlace para dc-sign. |
CA3079184A1 (fr) * | 2009-02-19 | 2010-08-26 | Glaxo Group Limited | Variants de liaison anti-albumine serique ameliores |
AU2013201618B2 (en) * | 2009-05-06 | 2016-06-02 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
BRPI1013990A2 (pt) | 2009-05-06 | 2019-04-30 | Biotest Ag | método para tratar uma doença , e, combinação anticâncer |
EP2555788B1 (fr) | 2010-03-24 | 2017-10-11 | Massachusetts Institute of Technology | Dimer du neuregulin pour un erbb/her récepteur pour utilisation dans la réduction de la cardiotoxicité |
WO2012009705A1 (fr) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Complexes liant ang-2 et leurs utilisations |
WO2012162561A2 (fr) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Complexes plurispécifiques multivalents et monovalents, et leurs utilisations |
KR20140100571A (ko) | 2011-12-08 | 2014-08-14 | 바이오테스트 아게 | Cd138을 타겟팅하는 면역접합체의 용도 |
WO2013185010A1 (fr) * | 2012-06-07 | 2013-12-12 | Duke University | Molécules entrant en contact avec un anticorps bispécifique humain contre egfrviii |
TWI660972B (zh) * | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗mcam抗體及相關使用方法 |
ITFI20120257A1 (it) * | 2012-11-26 | 2014-05-27 | Maria Barbara Carnemolla | Anticorpo ricombinante umano e suo uso per l¿identificazione di syndecano-1 (cd-138) per scopi diagnostici e terapeutici. |
CA2907181C (fr) | 2013-03-15 | 2023-10-17 | Viktor Roschke | Complexes multispecifiques multivalents et monovalents et leurs utilisations |
EP3049439B1 (fr) | 2013-09-26 | 2019-12-25 | Ablynx N.V. | Nanocorps bispécifiques |
CN105175546A (zh) * | 2015-05-27 | 2015-12-23 | 连祺周 | 人血管内皮生长因子与表皮生长因子样结构域7的融合蛋白 |
CA3004792A1 (fr) * | 2015-11-10 | 2017-05-18 | University Medical Center Hamburg - Eppendorf | Polypeptides de liaison d'antigene diriges contre cd38 |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
EP3471773A4 (fr) | 2016-06-21 | 2020-07-08 | Teneobio, Inc. | Anticorps se liant à cd3 |
JP7030109B2 (ja) | 2016-09-14 | 2022-03-04 | テネオバイオ, インコーポレイテッド | Cd3結合抗体 |
US11739163B2 (en) | 2016-09-29 | 2023-08-29 | Aebi Ltd. | Therapeutic multi-targeting constructs and uses thereof |
WO2018119215A1 (fr) | 2016-12-21 | 2018-06-28 | Teneobio, Inc. | Anticorps à chaîne lourde uniquement anti-bcma |
EP3642236A1 (fr) | 2017-06-20 | 2020-04-29 | TeneoOne, Inc. | Anticorps uniquement à chaînes lourdes anti-bcma |
EP3642237A2 (fr) | 2017-06-20 | 2020-04-29 | Teneobio, Inc. | Anticorps à chaîne lourde uniquement anti-bcma |
WO2019035938A1 (fr) * | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
SG11202002093TA (en) * | 2017-09-13 | 2020-04-29 | Teneobio Inc | Heavy chain antibodies binding to ectoenzymes |
CA3102039A1 (fr) * | 2018-06-05 | 2020-01-09 | Novobind Livestock Therapeutics Inc. | Anticorps contre des agents provoquant une maladie d'aquaculture et leurs utilisations |
CN109134611B (zh) * | 2018-08-14 | 2021-08-03 | 江苏大学 | 特异性结合egfr抑制egf促肿瘤细胞增殖的多肽 |
US20210388106A1 (en) * | 2018-10-26 | 2021-12-16 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
AU2019376632A1 (en) * | 2018-11-05 | 2021-06-17 | Xyphos Biosciences Inc. | Non-natural NKG2D receptors that do not directly signal the cells to which they are attached |
AR119746A1 (es) | 2019-06-14 | 2022-01-05 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
CN111732662B (zh) * | 2020-06-11 | 2023-09-15 | 军事科学院军事医学研究院军事兽医研究所 | 抗H5N1病毒入胞抗体PTD-7B-mFc及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2366718A3 (fr) * | 2002-06-28 | 2012-05-02 | Domantis Limited | Ligand |
EP1549345A1 (fr) * | 2002-10-10 | 2005-07-06 | MERCK PATENT GmbH | Anticorps bispecifiques contre erb utilises en therapie antitumorale |
GB0230203D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
ATE485307T1 (de) * | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
EP2535355B1 (fr) * | 2005-03-23 | 2019-01-02 | Genmab A/S | Anticorps dirigés contre CD38 pour le traitement du myélome multiple |
-
2006
- 2006-12-05 KR KR1020087016535A patent/KR20080090414A/ko not_active Application Discontinuation
- 2006-12-05 US US12/086,115 patent/US20100021473A1/en not_active Abandoned
- 2006-12-05 CA CA002632424A patent/CA2632424A1/fr not_active Abandoned
- 2006-12-05 WO PCT/GB2006/004565 patent/WO2007066109A1/fr active Application Filing
- 2006-12-05 TW TW095145117A patent/TW200738750A/zh unknown
- 2006-12-05 BR BRPI0619460-5A patent/BRPI0619460A2/pt not_active IP Right Cessation
- 2006-12-05 EP EP06808727A patent/EP1963370A1/fr not_active Withdrawn
- 2006-12-05 CN CNA200680052392XA patent/CN101426815A/zh active Pending
- 2006-12-05 EA EA200801171A patent/EA200801171A1/ru unknown
- 2006-12-05 AU AU2006323415A patent/AU2006323415A1/en not_active Abandoned
- 2006-12-05 CN CNA2006800523775A patent/CN101379088A/zh active Pending
- 2006-12-05 JP JP2008543894A patent/JP2009518025A/ja active Pending
-
2008
- 2008-05-19 ZA ZA200804307A patent/ZA200804307B/xx unknown
- 2008-05-26 NO NO20082381A patent/NO20082381L/no not_active Application Discontinuation
- 2008-06-02 MA MA30989A patent/MA30020B1/fr unknown
- 2008-06-20 CR CR10100A patent/CR10100A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200801171A1 (ru) | 2008-12-30 |
AU2006323415A1 (en) | 2007-06-14 |
MA30020B1 (fr) | 2008-12-01 |
US20100021473A1 (en) | 2010-01-28 |
CR10100A (es) | 2008-08-21 |
TW200738750A (en) | 2007-10-16 |
KR20080090414A (ko) | 2008-10-08 |
CN101379088A (zh) | 2009-03-04 |
EP1963370A1 (fr) | 2008-09-03 |
NO20082381L (no) | 2008-08-26 |
CN101426815A (zh) | 2009-05-06 |
WO2007066109A1 (fr) | 2007-06-14 |
CA2632424A1 (fr) | 2007-06-14 |
BRPI0619460A2 (pt) | 2011-11-08 |
JP2009518025A (ja) | 2009-05-07 |
WO2007066109A8 (fr) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200804307B (en) | Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor | |
IL192486A0 (en) | Ligands that have binding specificity for vegf and/or egfr and methods of use therefor | |
EP1868647A4 (fr) | Anticorps se liant à ov064 et leurs méthodes d'utilisation | |
IL198592A0 (en) | Tes7 and antibodies that bind thereto | |
HK1173734A1 (en) | Anti-mn antibodies and methods of using same mn | |
IL241091A0 (en) | Antibodies to fcrn and their use | |
EP2035831A4 (fr) | Procédés d'analyse d'interactions de liaison | |
EP2097534A4 (fr) | Anticorps humains se liant à cd70 et utilisations de ceux-ci | |
EP2041574A4 (fr) | Biomarqueurs du cancer et méthodes d'utilisation | |
EP1877079A4 (fr) | Ligands de proteine de liaison a l'elastine derives de plantes et leurs procedes d'utilisation | |
EP1871418A4 (fr) | Agents de liaison anti-cd70 humanises et utilisations | |
ZA200804594B (en) | Antibody molecules having specificity for human IL-6 | |
EP1846032A4 (fr) | Luca2 et anticorps s'y liant | |
HK1107402A1 (en) | Kid31 and antibodies that bind thereto kid31 | |
IL192419A0 (en) | Anti-ephb4 antibodies and methods using same | |
ZA200900058B (en) | Superabrasive materials and methods of manufacture | |
PL381358A1 (pl) | Sposoby i związki pośrednie | |
ZA200904657B (en) | Human antibodies that bind CD70 and uses thereof | |
PT1611890E (pt) | Métodos para avaliação e tratamento do cancro | |
ZA200708868B (en) | 7-Amino alkylidenyl-heterocyclic quinolones and napthyridones | |
IL231891A0 (en) | Anti-2ephriinb antibodies and methods of using them | |
EP1966603A4 (fr) | Fixation de molécules | |
PT1919951E (pt) | Anticorpos anti-tnfα e métodos de utilização | |
IL188450A0 (en) | Methods of determining pharmacokinetics of targeted therapies | |
EP1960535A4 (fr) | Composes et procedes d identification, de synthese, d optimisation et de creation de profils de modulateurs de proteines |